Serum levels of matrix metalloproteinase-9 predict lymph node metastasis in breast cancer patients

Heo,Dong Sik; Choi,Hoon; Yeom,Mi Young; Song,Byung Joo; Oh,Se Jeong

doi:10.3892/or.2014.3001

Serum levels of matrix metalloproteinase-9 predict lymph node metastasis in breast cancer patients

Authors:
- Dong Sik Heo
- Hoon Choi
- Mi Young Yeom
- Byung Joo Song
- Se Jeong Oh
View Affiliations

Affiliations: Department of Surgery, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Republic of Korea, Department of Clinical Research Laboratory, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Republic of Korea, Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Published online on: January 27, 2014 https://doi.org/10.3892/or.2014.3001
Pages: 1567-1572

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Matrix metalloproteinases (MMPs) are proteolytic enzymes that play important roles in cancer progression and metastasis. Although serum MMP expression is known to correlate with the primary lesion of breast cancer, there has yet to be a study regarding the correlation between serum MMP expression and metastatic lesions, particularly lymph nodes. The present study evaluated the correlation of serum and lymph node MMP expression with axillary node metastasis. The preoperative serum levels of MMP-2 and MMP-9 in 77 patients with breast cancer and in 10 patients with benign breast tumor were determined by ELISA and zymography. One hundred and twelve axillary lymph nodes were collected for zymography during breast cancer surgery. Significantly higher serum levels of MMP-2 and MMP-9 were found in breast cancer patients compared to patients with benign tumor. High serum levels of MMP-2 and MMP-9 were significantly associated with node metastasis. ELISA and zymography results for serum MMP-2 and MMP-9 correlated significantly, with a Pearson correlation coefficient (r) of 0.76 for MMP-2 (P=0.001) and 0.81 for MMP-9 (P=0.001). In terms of lymph node, total MMP-2, MMP-9 and MMP-9 activity were significantly higher in metastatic than in non-metastatic nodes. There was a correlation between serum and lymph node MMP-9 levels on zymographic measurements (r=0.34, P=0.011), but not in terms of MMP-2 levels. Serum MMP-9 levels may have a diagnostic value for predicting axillary node metastasis.

View Figures

View References

1	Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B and Senn HJ: Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 16:1569–1583. 2005. View Article : Google Scholar : PubMed/NCBI
2	Thomssen C and Janicke F: Do we need better prognostic factors in node-negative breast cancer? Eur J Cancer. 36:293–298. 2000. View Article : Google Scholar : PubMed/NCBI
3	Talvensaari-Mattila A, Paakko P, Hoyhtya M, Blanco-Sequeiros G and Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer. 83:1153–1162. 1998. View Article : Google Scholar : PubMed/NCBI
4	Li HC, Cao DC, Liu Y, et al: Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat. 88:75–85. 2004. View Article : Google Scholar : PubMed/NCBI
5	Giambernardi TA, Grant GM, Taylor GP, et al: Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol. 16:483–496. 1998. View Article : Google Scholar : PubMed/NCBI
6	Iwasaki M, Nishikawa A, Fujimoto T, et al: Anti-invasive effect of MMI-166, a new selective matrix metalloproteinase inhibitor, in cervical carcinoma cell lines. Gynecol Oncol. 85:103–107. 2002. View Article : Google Scholar : PubMed/NCBI
7	Kato Y, Yamashita T and Ishikawa M: Relationship between expression of matrix metalloproteinase-2 and matrix metalloproteinase-9 and invasion ability of cervical cancer cells. Oncol Rep. 9:565–569. 2002.PubMed/NCBI
8	McMasters KM, Giuliano AE, Ross MI, et al: Sentinel-lymph-node biopsy for breast cancer - not yet the standard of care. N Engl J Med. 339:990–995. 1998. View Article : Google Scholar : PubMed/NCBI
9	Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R and Murray GI: Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res. 10:8229–8234. 2004. View Article : Google Scholar
10	Forget MA, Desrosiers RR and Beliveau R: Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can J Physiol Pharmacol. 77:465–480. 1999. View Article : Google Scholar : PubMed/NCBI
11	Duffy MJ, Maguire TM, Hill A, McDermott E and O’Higgins N: Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2:252–257. 2000. View Article : Google Scholar : PubMed/NCBI
12	Giannelli G, Bergamini C, Fransvea E, Marinosci F, Quaranta V and Antonaci S: Human hepatocellular carcinoma (HCC) cells require both alpha3beta1 integrin and matrix metalloproteinases activity for migration and invasion. Lab Invest. 81:613–627. 2001. View Article : Google Scholar
13	Vasala K, Paakko P and Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer. Urology. 62:952–957. 2003. View Article : Google Scholar : PubMed/NCBI
14	Gerhards S, Jung K, Koenig F, et al: Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology. 57:675–679. 2001. View Article : Google Scholar : PubMed/NCBI
15	Liabakk NB, Talbot I, Smith RA, Wilkinson K and Balkwill F: Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res. 56:190–196. 1996.
16	Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 284:67–68. 1980. View Article : Google Scholar : PubMed/NCBI
17	Davies B, Miles DW, Happerfield LC, et al: Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer. 67:1126–1131. 1993. View Article : Google Scholar : PubMed/NCBI
18	Brown PD, Bloxidge RE, Anderson E and Howell A: Expression of activated gelatinase in human invasive breast carcinoma. Clin Exp Metastasis. 11:183–189. 1993. View Article : Google Scholar : PubMed/NCBI
19	Di Carlo A, Terracciano D, Mariano A and Macchia V: Matrix metalloproteinase-2 and matrix metalloproteinase-9 type IV collagenases in serum of patients with pleural effusions. Int J Oncol. 26:1363–1368. 2005.PubMed/NCBI
20	Daniele A, Zito AF, Giannelli G, et al: Expression of metalloproteinases MMP-2 and MMP-9 in sentinel lymph node and serum of patients with metastatic and non-metastatic breast cancer. Anticancer Res. 30:3521–3527. 2010.PubMed/NCBI
21	Hanemaaijer R, Verheijen JH, Maguire TM, et al: Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int J Cancer. 86:204–207. 2000. View Article : Google Scholar : PubMed/NCBI
22	Zucker S, Hymowitz M, Conner C, et al: Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann NY Acad Sci. 878:212–227. 1999. View Article : Google Scholar : PubMed/NCBI
23	Kjeldsen L, Bjerrum OW, Hovgaard D, Johnsen AH, Sehested M and Borregaard N: Human neutrophil gelatinase: a marker for circulating blood neutrophils. Purification and quantitation by enzyme linked immunosorbent assay. Eur J Haematol. 49:180–191. 1992. View Article : Google Scholar : PubMed/NCBI
24	Ranuncolo SM, Armanasco E, Cresta C, Bal De Kier Joffe E and Puricelli L: Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer. 106:745–751. 2003. View Article : Google Scholar : PubMed/NCBI